This segment focuses on the development and commercialization of diagnostic imaging agents for various cancers, particularly prostate and kidney cancer. Key activities include the development of PSMA PET/CT technology for prostate cancer diagnosis, which represents a breakthrough in the field. The segment leverages radiopharmaceutical technology to create targeted imaging agents that enable precise detection and staging of tumors. Clinical trials are a crucial part of this segment, with ongoing studies to validate the efficacy and safety of new imaging agents. The goal is to improve patient outcomes by providing clinicians with better tools for early detection and accurate diagnosis, leading to more effective treatment strategies. This segment also includes the development and regulatory approval of imaging agents like Illuccix® and Zircaix®.

This segment is dedicated to developing and commercializing therapeutic radiopharmaceuticals for targeted cancer treatment. The focus is on using molecularly targeted radiation (MTR) to deliver radiation directly to cancer cells, minimizing damage to healthy tissue. Research and development efforts include the creation of novel isotopes and delivery methods, such as targeted alpha therapy using TLX592 for prostate cancer. Clinical trials are essential for evaluating the safety and efficacy of these therapies, with ongoing studies for metastatic castrate-resistant prostate cancer (TLX591) and glioblastoma (TLX101). The segment aims to provide patients with advanced treatment options that offer improved outcomes and reduced side effects. This includes strategic partnerships to expand the therapeutic pipeline and enhance manufacturing capabilities for radiopharmaceuticals.